Three-dimensional (3D) imaging of tumor angiogenesis and its inhibition: Evaluation of tumor vascular-targeting agent efficacy in the DMBA-induced rat breast cancer model by confocal laser scanning microscopy (CLSM)

Acta Histochemica et Cytochemica

Volumn 36, Issue 1, 2003, Pages 27-36

  Itoh, Johbu ^a   Yasumura, Kazuhiko ^b   Ogawa, Kenji ^b   Kawai, Kenji ^a   Serizawa, Akihiko ^a   Yamamoto, Yukito ^b   Osamura, Yoshiyuki R ^a  

^a TOKAI UNIVERSITY   (Japan)

^b NKK Hospital   (Japan)

Author keywords

CLSM; DMBA rat mammary cancer; FITC conjugated gelatin injection method; Tumor angiogenesis; Tumor vascular targeting agent

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DIMETHYLBENZ[A]ANTHRACENE; DOCETAXEL; FLUORESCEIN ISOTHIOCYANATE; FUMAGILLOL CHLOROACETYLCARBAMATE; GELATIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADOLESCENT; ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BREAST CANCER; CANCER MODEL; CANCER SURVIVAL; CAPILLARY DENSITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FEMALE; INJECTION; METASTASIS; MICROVASCULATURE; NONHUMAN; RAT; TECHNIQUE; THREE DIMENSIONAL IMAGING; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALIA;

EID: 0037660388     PISSN: 00445991     EISSN: None     Source Type: Journal    
DOI: 10.1267/ahc.36.27     Document Type: Article

References (50)

1. Ascherman, J. A., Knowles, S. L. and Attkiss, K. (2000) Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann. Plast. Surg. 45; 438-441.
2. Beecken, W. D., Fernandez, A., Panigrahy, D., Achilles, E. G., Kisker, O., Flynn, E., Joussen, A. M., Folkman, J. and Shing, Y. (2000) Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology 56;521-526.
3. Berse, B., Brown, L. F., Van de Water, L., Dvorak, H. F. and Senger, D. R. (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell 3; 211- 220.
4. Bicknell, R. and Harris, A. L. (1991) Novel growth regulatory factors and tumor angiogenesis. Eur. J. Cancer 27; 781-785.
5. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F. and Senger, D. R. (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143; 1255-1262.
6. Chaplin, D. J., Pettit, G. R., Parkins, C. S. and Hill, S. A. (1996) Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer Suppl. 27; S86-88.
7. Chaplin, D. J. and Dougherty, G. J. (1999) Tumour vasculature as a target for cancer therapy. Br. J. Cancer 80 (Suppl 1); 57-64.
8. Cirri, L., Donnini, S., Morbidelli, L., Chiarugi, P., Ziche, M. and Ledda, F. (1999) Endostatin: a promising drug for antiangiogenic therapy. Int. J. Biol. Markers 14; 263-267.
9. Couteau, C., Risse, M. L., Ducreux, M., Lefresne-Soulas, F., Riva, A., Lebecq, A., Ruffie, P., Rougier, P., Lokiec, F., Bruno, R. and Armand, J. P. (2000) Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J. Clin. Oncol. 18; 3545-3552.
10. Dykes, D. J., Bissery, M. C., Narrison, S. D. Jr and Waud, W. R. (1995) Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest. New Drugs 13; 1-11.
11. Ergun, S., Kilik, N., Ziegeler, G., Hansen, A., Nollau, P., Gotze, J., Wurmbach, J. H., Horst, A., Weil, J., Fernando, M. and Wagener, C. (2000) CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol. Cell 5; 311-320.
12. Folkman, J. and Ingber, D. E. (1987) Angiostatic steroids: method of discovery and mechanism of action. Ann. Surg. 206; 374-383.
13. Folkman, J. (1990) What is the evidence that tumor are angiogenesis dependent? J. Natl. Cancer Inst. 82; 4-6.
14. Folkman, J. (1995) The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res. Treat. 36; 109-118.
15. Gagliardi, A., Hadd, H. and Collins, D. C. (1992) Inhibition of angiogenesis by suramin. Cancer Res. 52; 5073-5075.
16. Gasparini, G. (1999) The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 58; 17-38.
17. Gervaz, P., Scholl, B., Padrun, V. and Gillet, M. (2000) Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470. Liver 20; 108-113.
18. Hagedorn, M. and Bikfalvi, A. (2000) Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit. Rev. Oncol. Hematol. 34; 89-110.
19. Hill, S. A., Sampson, L. E. and Chaplin, D. J. (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer 63; 119-123.
20. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S. and Thorpe, P. E. (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275; 547-550.
21. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H. and Folkman, J. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348; 555-557.
22. Itoh, J., Yasumura, K., Takeshita, T., Ishikawa, H., Kobayashi, H., Ogawa, K., Kawai, K., Serizawa, A. and Osamura, R. Y. (2000) Three-dimensional imaging of tumor angiogenesis. Anal. Quant. Cytol. Histol. 22; 85-90.
23. Itoh, J., Kawai, K., Serizawa, A., Yasumura, K., Ogawa, K. and Osamura, R. Y. (2000) A new approach to three-dimensional reconstructed imaging of hormone-secreting cells and their microvessel environments in rat pituitary glands by confocal laser scanning microscopy. J. Histochem. Cytochem. 48; 569-578.
24. Itoh, J., Matsuno, A., Yamamoto, Y., Kawai, K., Serizawa, A., Watanabe, K., Itoh, Y. and Osamura, R. Y. (2001) Confocal laser scanning microscopic imaging of subcellular organelles, mRNA, protein products, and the microvessel environment. Acta Histochem. Cytochem. 34; 285-297.
25. Itoh, J., Serizawa, A., Kawai, K., Ishii, Y., Teramoto, A. and Osamura, R. Y. (2003) Vascular networks and endothelial cells in the rat experimental pituitary glands and in the human pituitary adenomas. Microsc. Res. Tech. 60; 231-235.
26. Kaidoh, T., Yasugi, T. and Uehara, Y. (1991) The microvasculature of the 7,12-dimethylbenz (a) anthracene (DMBA)-induced rat mammary tumour. I. Vascular patterns as visualized by scanning electron microscopy of corrosion casts. Virchows Arch. A Pathol. Anal. Histopathol. 418; 111-117.
27. Kakeji, Y. and Teicher, B. A. (1997) Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest. New Drugs. 15; 39-48.
28. Kerbel, R. S., Viloria-Petit, A., Klement, G. and Rak, J. (2000) 'Accidental' anti-angiogenic drugs anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer 36; 1248-1257.
29. Klauber, N., Parangi, S., Flynn, E., Hamel, E. and D'Amato, R. J. (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57; 81-86.
30. Kokufu, I., Taniguchi, H., Kim, Y. H., Fukuda, K., Yamamoto, M., Yano, T., Yamada, K., Kitano, H. and Fukuda, H. (2000) A case of effective chemotherapy using CAF followed by docetaxel for advanced breast cancer. Gan To Kagaku Ryoho 27; 1577-1580. (in Japanese)
31. Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D. and Folkman, J. (1994) Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer 69; 212-216.
32. Moon, C., Verschraegen, C. F., Bevers, M., Freedman, R., Kudelka, A. P. and Kavanagh, J. J. (2000) Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 11; 565-568.
33. Moulton, K. S., Heller, E., Konerding, M. A., Flynn, E., Palinski, V. and Folkman, J. (1999) Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99; 1726-1732.
34. Nakane, P. K. (1975) Recent progress in the peroxidase-labeled antibody method. Ann. NY Acad. Sci. 234; 203-244.
35. Oikawa, T., Hirotani, K., Shimamura, M., Ashino-Fuse, H. and Iwaguchi, T. (1989) Powerful antiangiopgenic activity of herbimcin A. J. Antibiot. 42; 1202-1204.
36. Olson, T. A., Mohanraj, D., Carson, L. F. and Ramakrishnan, S. (1994) Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 54; 276-280.
37. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R. and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88; 277-285.
38. Pagani, O., Sessa, C., Nole, F., Crivellari, D., Lombardi, D., Thurlimann, B., Hess, D., Borner, M., Bauer, J., Martinelli, G., Graffeo, R., Zucchetti, M., D'Incalci, M. and Goldhirsch, A. (2000) Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann. Oncol. 11; 985-991.
39. Pepper, M. S., Ferrara, N., Orci, L. and Montesano, R. (1992) Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 189; 824-831.
40. Plate, K. H., Breier, G., Weich, H. A. and Risau, W. (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359; 845-848.
41. Schimming, R., Mason, K. A., Hunter, N., Weil, M., Kishi, K. and Milas, L. (1999) Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother. Pharmacol. 43; 165-172.
42. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219; 983-985.
43. Suzuma, T., Sakurai, T., Yoshimura, G., Umemura, T., Tamaki, T. and Naito, Y. (2000) Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer. Anticancer Drugs 11; 569-571.
44. Toi, M., Yamamoto, Y., Imazawa, T., Takayanagi, T., Akutsu, K. and Tominaga, T. (1993) Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int. J. Oncol. 3; 525-528.
45. Twardowski, P. and Gradishar, W. J. (1997) Clinical trials of antiangiogenic agents. Curr. Opin. Oncol. 9; 584-589.
46. Wild, R., Dhanabal, M., Olson, T. A. and Ramakrishnan, S. (2000) Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells. Br. J. Cancer 83; 1077-1083.
47. Yasumura, K., Ogawa, K., Nakagawa, Y., Yuasa, Y., Hiramatsu, H., Hiramatsu, K. and Osamura, R. Y. (1997) Dynamic MR imaging and tumor angiogenesis in DMBA-induced rat breast cancer; Three dimensional (3D) reconstructed image analysis of tumor microvessels by confocal laser scanning microscopy. Breast Cancer 4; 291-296.
48. Yoshizawa, J., Mizuno, R., Yoshida, T., Hara, A., Ashizuka, S., Kanai, M., Kuwashima, N., Kurobe, M. and Yamazaki, Y. (2000) Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma. J. Surg. Res. 93; 82-87.
49. Zeng, S., Chen, Y. Z., Fu, L., Johnson, K. R. and Fan, W. (2000) In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin. Cancer Res. 6; 3766-3773.
50. Zhang, Y., Griffith, E. C., Sage, J., Jacks, T. and Liu, J. O. (2000) Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. USA 97: 6427-6432.